Pliant’s chronic liver disease drug has consistent safety across dose ranges, PhII data show
The highest dose of Pliant Therapeutics’ bexotegrast does not have improved activity over lower doses according to new biomarker data from a mid-stage primary sclerosing …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.